#ATTRCM
LightNews LightNews
rcatanho.bsky.social
Disfunción auricular izquierda es común en pacientes con amiloidosis trantiretina con cardiomiopatía y representa peor pronóstico, y vutisiran atenúa el empeoramiento en la tensión auricular izquierda a los 30m #vutisiran #ATTRCM jamanetwork.com/journals/jam...
Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy
This secondary analysis of the HELIOS-B randomized clinical trial evaluates the prognostic significance of left atrial structure and function among patients with transthyretin amyloidosis with cardiom...
jamanetwork.com
September 2, 2026 at 9:29 AM
jaccjournals.bsky.social
Vutrisiran benefits were consistent across baseline tafamidis use, with reduced effect size observed in those on stabilizers. Findings support further study of combination therapy. https://bit.ly/45R2LuY

#ESCCongress #JACC #ATTRCM #CardioSky
August 30, 2026 at 12:20 PM
gmj-georgia.bsky.social
Long-term data from Nature Medicine's NI006-101 trial show cliramitug—a monoclonal antibody against misfolded transthyretin—sustains clinical benefit…

#ATTRCM #Cardiacamyloidosis #Cardiomyopathy #Cliramitug #Monoclonalantibody

#ATTRCM #Cardiacamyloidosis #Cardiomyopathy #Cliramitug #Monoclonala…
Monoclonal antibody cliramitug sustains benefit in cardiac amyloidosis
Long-term data from Nature Medicine's NI006-101 trial show cliramitug—a monoclonal antibody against misfolded transthyretin—sustains clinical benefit… #ATTRCM #Cardiacamyloidosis #Cardiomyopathy #Cliramitug #Monoclonalantibody
news.gmj.ge
August 21, 2026 at 1:30 PM
med-iqcardiology.bsky.social
18/New insights in ATTR-CM—Patients on tafamidis showed greater functional stability at 12 months, and that stability strongly predicted survival. Early preservation of function matters. #ATTRCM
Infographic summarizing tafamidis post hoc findings in ATTR-CM: higher functional stability at 12 months, functional stability strongly predictive of survival, 73% lower mortality in stable patients, and lower CV hospitalization rates vs placebo. Second slide: Bullet summary of tafamidis impact on mortality and hospitalization, showing lower mortality in stable vs progressing patients, reduced CV hospitalizations even with functional decline, and benefit across functional trajectories.
June 30, 2026 at 7:38 PM
jamacardiology.com
Early and continuous acoramidis treatment in #ATTRCM yields sustained reductions in mortality and cardiovascular hospitalization, stabilizes biomarkers and health status, and exhibits durable safety through 54 months. ja.ma/4f3mNIq
JAMA Cardiology article titled, "Long-Term Durability of Acoramidis Efficacy..." includes Kaplan-Meier curves for Time to All-Cause Mortality ([ACM]@number) and Cardiovascular-Related Mortality ([CVM]@number) through Month 54, comparing Continuous Acoramidis vs. Placebo.
May 23, 2026 at 11:00 AM
mdspirenews.bsky.social
Starting acoramidis early matters.

Continuous treatment was linked to a 45% lower risk of all-cause mortality in ATTR-CM over 54 months.

More: https://ow.ly/Tcsh50YKqjM

#Cardiology #ATTRCM
Acoramidis Linked to Lower Mortality Through 54 Months
Early treatment was associated with sustained reductions in mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy
ow.ly
April 23, 2026 at 1:00 PM
rcatanho.bsky.social
Tratamiento continuo durante 54m con acoramidis reduce la mortalidad por todas las causas y por causas CV, y la primera hospitalización por causas CV hasta los 54 m en pacientes con cardiomiopatía por amiloide transtiretina #ATTRCM #acoramidis jamanetwork.com/journals/jam...
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy
This open-label extension of the ATTRibute-CM randomized clinical trial evaluates the long-term efficacy and safety of acoramidis through month 54.
jamanetwork.com
April 6, 2026 at 6:01 AM
jamacardiology.com
Early and continuous acoramidis treatment in #ATTRCM yields sustained reductions in mortality and cardiovascular hospitalization, stabilizes biomarkers and health status, and exhibits durable safety through 54 months.

#ACC26 @accintouch.bsky.social

ja.ma/4bGqr9d
JAMA Cardiology article presents Kaplan-Meier curves for time to all-cause mortality (ACM) and cardiovascular-related mortality (CVM) through month 54. Graphs compare continuous acoramidis to placebo, showing survival probability over time with stratified Cox regression analysis.
March 30, 2026 at 7:00 PM
nmqf.bsky.social
This Black History Month, we honor our history by protecting our future. ATTR-CM is a rare but serious heart condition that often goes undiagnosed—especially in Black communities.
Learn the signs. Ask your doctor.
Visit AskAboutATTR.org to learn more.
#BlackHistoryMonth #ATTRCM #LiftEveryVoice
February 3, 2026 at 5:12 PM
rarediseaseadvisor.bsky.social
Accurate differentiation between light-chain (AL) amyloidosis and #ATTRCM is critical for effective patient management, as misclassification can delay life-saving therapies for #ALAmyloidosis or result in unnecessary interventions for ATTR-CM.

Learn more: https://bit.ly/4q8BrAH
AL Amyloidosis vs ATTR-CM: Clinical Insights and Diagnostic Challenges
This article explores key differences and diagnostic challenges between light-chain amyloidosis and ATTR-CM.
bit.ly
January 6, 2026 at 8:54 PM
rarediseaseadvisor.bsky.social
Significant conduction abnormalities were more frequent than overt #AmyloidCardiomyopathy (CM) in patients with the #V30M mutation in the #Transthyretin (TTR) gene.

Learn more: https://bit.ly/4aQdXeP

#RareDisease #ATTRCM #TTRGene #MedSky
Conduction Abnormalities Appear More Common Than Cardiomyopathy in Patients With TTR V30M
Significant conduction abnormalities were more frequent than overt amyloid cardiomyopathy in patients with TTR V30M, per a new study.
www.rarediseaseadvisor.com
December 16, 2025 at 4:41 PM
rarediseaseadvisor.bsky.social
Physical performance is “remarkably compromised” in patients with transthyretin-mediated amyloid cardiomyopathy (#ATTRCM), as measured by the 6-minute walk test. Study in BMC Cardiovascular Disorders.

Read more: https://bit.ly/4aAfJAM

#RareDisease #Cardiology #PhysicalPerformance #MedSky
Six-Minute Walk Distance May Be Associated With Disease Severity in ATTR-CM
A recent study shows physical performance is “remarkably compromised” in patients with ATTR-CM, as measured by the 6-minute walk test.
bit.ly
December 12, 2025 at 6:51 PM
rarediseaseadvisor.bsky.social
Increased mechanical dispersion is associated with advanced stages of transthyretin-mediated amyloid cardiomyopathy (#ATTRCM) and mortality, according to a new study published in Scientific Reports.

Read here: https://bit.ly/3MdhvxH

#RareDisease #MedSky
Study Identifies Potential New Marker of ATTR-CM
Increased mechanical dispersion may serve as a marker of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
bit.ly
December 3, 2025 at 5:50 PM
rarediseaseadvisor.bsky.social
Happy HallowThankMas! 🎃 🦃 🎄

ATTR-CM Contributor Faye Adams is celebrating the season a little differently this year — by creating moments whenever she can, not just when the calendar says it’s time.

✨Read more here: https://bit.ly/47ZFb10

#RareDisease #ATTRCM #RareVoices #MedSky
November 26, 2025 at 3:47 PM
4040rec.bsky.social
#AlnylamUK #NICE #vutrisiran #Amvuttra #ATTRCM #NICEfinaldraftguidance #transthyretinamyloidosiswithcardiomyopathy #hereditaryATTR #stage1polyneuropathy #stage2polyneuropathy #NICEfinalguidance #HELIOSBstudy #cardiovascular #stiffheartdisease #AnnaTomlinson #CardiomyopathyUK
zurl.co/0yB9A
NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance - PharmaTimes
First long-acting therapy with three-monthly dosing to target root cause of cardiac disease
pharmatimes.com
November 26, 2025 at 1:02 PM
rarediseaseadvisor.bsky.social
Clinical symptoms, serum biomarkers, and imaging parameters worsened substantially after 2 years in patients with transthyretin-mediated amyloid cardiomyopathy (#ATTRCM), whether or not they were treated with #Tafamidis. Study in Clinical Research in Cardiology.

Read more: https://bit.ly/4pun9d5
Tafamidis May Slow the Progression of ATTR-CM
Clinical symptoms, serum biomarkers, and imaging parameters worsened substantially after 2 years in patients with ATTR-CM, per a recent study.
bit.ly
November 25, 2025 at 4:44 PM
rarediseaseadvisor.bsky.social
Transthyretin amyloid (#ATTR) fibrils caused by the T60A TTR gene variant, which is associated with a mixed cardiac (#ATTRCM) and neuropathic (#ATTRPN), have a single morphology across patients and tissues. Study in Structure.

Read more: https://bit.ly/3M7nbsM

#RareDisease #Cardiology
Structural Homogeneity a Hallmark of Cardiac, Mixed Phenotypes in ATTR
ATTR fibrils caused by the T60A TTR gene variant have a single morphology but high compositional homogeneity, according to recent research.
bit.ly
November 17, 2025 at 7:03 PM
rarediseaseadvisor.bsky.social
#AHA25: Researchers developed a machine learning model that outperforms the Mayo #ATTRCM score in differentiating the disease from other #CardiacConditions. Presented at the @americanheart.bsky.social Scientific Sessions 2025.

Read more: https://bit.ly/441KpXt

#RareDisease #MedTech #Cardiology
AI Tool Successfully Distinguishes ATTR-CM From Other Diseases
A new machine learning model performed better than the Mayo ATTR-CM score in discerning ATTR-CM from other heart conditions.
bit.ly
November 8, 2025 at 8:15 PM
rarediseaseadvisor.bsky.social
#AHA25: While #Transthyretin (TTR) stabilizers reduce the risk of cardiovascular events in patients with #ATTRCM in a real-world setting, data on #TTR gene silencers is more limited. Presented at the @americanheart.bsky.social Scientific Sessions 2025.

Read more: https://bit.ly/485pntu
Real-World Analysis Supports Efficacy of ATTR-CM Therapies
A retrospective analysis of patient health records found that transthyretin stabilizers show clinical benefit in adults with ATTR-CM.
bit.ly
November 8, 2025 at 7:48 PM
asnc.bsky.social
"We're entering an era where patients should expect not to die 𝘧𝘳𝘰𝘮 cardiac #amyloidosis but rather 𝘸𝘪𝘵𝘩 it.” — Dr. Michelle Kittleson

Early diagnosis + treatment are changing outcomes in #ATTRCM. Age-expected longevity may be w/in reach.
Read🔗 bit.ly/4qBtZid

Sponsored by Alnylam Pharmaceuticals
November 4, 2025 at 3:44 PM
accintouch.bsky.social
🆕 Concise Clinical Guidance addresses evaluation & management of #ATTRCM & provides updated strategies & best practices, taking into account expanding disease modifying therapies, #heartfailure therapies & potential future opportunities.

More: 🔗 https://bit.ly/4qBQvYd #JACC #Amyloidosis #CardioSky
October 31, 2025 at 7:10 PM
jaccjournals.bsky.social
New ACC Concise Clinical Guidance updates best practices for diagnosing and managing transthyretin amyloid #cardiomyopathy, highlighting disease-modifying and HF therapies plus future directions. https://bit.ly/49nYX7m

#JACC #Amyloidosis #ATTRCM #HeartFailure #CardioSky
October 31, 2025 at 2:05 PM
rarediseaseadvisor.bsky.social
#LiverTransplantation and treatment with disease-modifying therapies significantly improve survival in patients with hereditary variant transthyretin amyloidosis, which can lead to cardiomyopathy (#ATTRCM) and polyneuropathy (#ATTRPN). @jinternmed.bsky.social

Read more: https://bit.ly/48j6jZt
Platelets Play a Key Role in MG Pathogenesis
A new study supports the notion that activated platelets play a key role in the pathogenesis of myasthenia gravis (MG).
bit.ly
October 7, 2025 at 7:11 PM
jaccjournals.bsky.social
Acoramidis 📉 cumulative CV outcomes in #ATTRCM vs placebo, w/ numerical differences by month 1 & 📈 through month 30 (53 events avoided/100 pts). Nearly 1/4 of events occurred in the first 6 months, underscoring the need for timely Tx https://bit.ly/4gLv5DG

#HFSA2025 #JACC #CardioSky
September 28, 2025 at 2:22 PM
jaccjournals.bsky.social
New in #JACC: A cross-trial analysis of 3 cardiac amyloidosis #ATTRCM trials reveals time-dependent effects of modern disease-modifying therapies on mortality.

Get the details: www.jacc.org/doi/10.1016/...

#ATTRMeeting2025 #ATTR2025 #Amyloidosis #CardioSky
September 25, 2025 at 1:25 PM